Subscribe for the newsletter
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Clinical Trials
Filter
Filter
Sort By
Newest First
1 / 40
Sector
Modality / Product
Reset
1 / 40
Sign in
Clinical Trials
Gene Therapeutics (NGGT) Announces Publication of Early Clinical Trial Results for the Treatment of Bietti's Crystalline Dystrophy
NGGT Inc.
PR-01-25-NI-16
Jan 16, 2025
Clinical Trials
Chime Biologics and Mabgeek Achieve MG-K10 PPQ Milestone, Advancing Therapies Clinical Trials and Commercialization
Chime Biologics
PR-01-25-NI-01
Jan 03, 2025
CDMO
Navigating the Complexities of Microbial and Mammalian Manufacturing
Peter Boman; Helena Pettersson
NorthX Biologics
PAO-12-24-CL-3
Jan 02, 2025
Clinical Trials
GenBio AI Releases Phase 1 of World's First Digital Organism to Transform Medical Research
GenBio AI
PR-12-24-NI-144
Dec 19, 2024
Clinical Trials
Beacon Therapeutics Announces Positive 3-Month Data from Phase 2 DAWN Trial in Patients
Beacon Therapeutics
PR-12-24-NI-131
Dec 06, 2024
CDMO
Advancing the Science of Technical and Therapeutic Proteins
Eva-Karin Gidlund, Ph.D.
NorthX Biologics
PAO-11-24-CL-10
Dec 04, 2024
Antibody
Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies
Spyre Therapeutics, Inc.
PR-12-24-NI-125
Dec 03, 2024
Financing
EQT Life Sciences leads €54 Million Series A Financing of ATB Therapeutics
EQT
PR-11-24-NI-116
Nov 20, 2024
CRO
Lindus Health Rolls Out "All-in-One Infectious Disease CRO" Bespoke to Clinical Trials for Infectious Disease Interventions
Lindus Health
PR-11-24-NI-113
Nov 19, 2024
Clinical Trials
Concerto Biosciences Announces First Participant Dosed with Live Biotherapeutic ENS-002 in Phase 1 Trial for Atopic Dermatitis
Concerto Biosciences
PR-11-24-NI-112
Nov 19, 2024
Commissioning
Navigating the Australian Clinical Trials Landscape
CAI Commissioning Agents Inc.
PAO-11-24-RTM-05
Nov 15, 2024
Cystic Fibrosis
Spirovant Sciences Doses First Patient in Phase 1/2 Trial of Its Aerosol-Delivered Genetic Medicine for Treating Cystic Fibrosis
Spirovant Sciences
PR-11-24-NI-101
Nov 15, 2024
Clinical Trials
Moleculin Receives Institutional Review Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin for the Treatment
Moleculin Biotech, Inc.
PR-10-24-NI-93
Nov 12, 2024
NKTR-255
Nektar Presents Late-breaking Results from Phase 2 Study of NKTR-255 for the Treatment of Radiation Induced Lymphopenia
Nektar Therapeutics
PR-10-24-NI-85
Nov 08, 2024
Clinical Trials
Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma
Carisma Therapeutics Inc.
PR-10-24-NI-89
Nov 08, 2024
Large Molecule
Johnson & Johnson Submits Applications Seeking Approval as Subcutaneous Monotherapy for High-Risk moldering Multiple Myeloma
Johnson & Johnson
PR-10-24-NI-88
Nov 08, 2024
Clinical Trials
Samsung Biologics earns ISO certifications in recognition of business excellence
Samsung Biologics
PR-10-24-NI-86
Nov 08, 2024
Clinical Trials
GenomOncology and Genomenon Partner to Enhance Germline Variant Classification and Genomic Reporting
GenomOncology
PR-10-24-NI-82
Nov 07, 2024
FDA
HuidaGene Therapeutics Receives the First-Ever FDA Clearance of CRISPR/Cas13 RNA-Editing HG202 for Macular Degeneration
HuidaGene Therapeutics
PR-10-24-NI-81
Nov 07, 2024
Clinical Trials
Transposon to Present Results from Phase 2 Study for the Treatment of ALS/FTD at the 7th Annual ALS ONE Research Symposium
Transposon Therapeutics
PR-10-24-NI-79
Nov 07, 2024
